NYSE$NEUE
NeueHealth Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported financial results for the third quarter ended September 30, 2022.
Bright Health Group reported a revenue of $1.6 billion, a 51.3% increase from Q3 2021. The company experienced a GAAP Net Loss of $259.4 million and an Adjusted EBITDA Loss of $82.9 million. They are lowering the Full Year 2022 Enterprise Medical Cost Ratio guidance range to 90% to 92% and positively revising the Full Year 2022 Adjusted EBITDA loss guidance range to $550 to $700 million.
- Revenue of $1.6 billion, up 51.3% from Q3'21.
- GAAP Net Loss of $259.4 million.
- Adjusted EBITDA Loss of $82.9 million.
- Q2’22 Enterprise Medical Cost Ratio of 90.6%, a strong improvement from the prior year.
Headline financials
Revenue & EPS history
NeueHealth · Revenue · Quarterly
$1.63B
Forward guidance
Bright Health Group expects total revenue of $6.8 billion and an enterprise Medical Cost Ratio between 90% and 92% for full year 2022. Bright HealthCare combined Commercial and Medicare Advantage end-of-year membership is expected to be over 1,000,000, while NeueHealth Revenue is expected to be approximately $2.2 billion. Adjusted EBITDA for 2022 is expected to be a loss of between $500.0 million and $700.0 million
Tailwinds
- Total Revenue is expected to be $6.8 billion.
- Enterprise Medical Cost Ratio between 90% and 92%.
- Bright HealthCare combined Commercial and Medicare Advantage end-of-year membership is expected to be over 1,000,000.
- NeueHealth Revenue is expected to be approximately $2.2 billion.
- Intercompany Revenue elimination, comprised of payments from Bright HealthCare to NeueHealth for managing patient care and for network services, is expected to be approximately $1.2 billion.
Headwinds
- Adjusted EBITDA for 2022 is expected to be a loss of between $500.0 million and $700.0 million
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2022
-2.0%
Avg return
Earnings day
-6.9%
Avg return
5 days after
-17.7%
Avg return
30 days after
45%
10 / 22 earnings
Positive
+46.5%
Q1 2023
Best reaction
-43.1%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | +0.0% | -2.2% | -2.1% | |
| Q1 2025 | -2.2% | -0.4% | -1.5% | |
| Q4 2024 | +8.9% | +30.9% | +29.9% | |
| Q3 2024 | +2.2% | +2.5% | +7.8% | |
| Q2 2024 | -3.6% | +2.3% | -4.4% | |
| Q1 2024 | -4.0% | -3.7% | -14.3% | |
| Q4 2023 | +7.6% | -6.0% | -27.7% | |
| Q3 2023 | -1.5% | -10.2% | -15.5% | |
| Q2 2023 | -21.8% | -27.8% | -61.3% | |
| Q1 2023 | +46.5% | +7.2% | -14.1% | |
| Q4 2022 | -43.1% | -48.8% | -77.2% | |
| Q3 2022 | +4.3% | -3.7% | -15.3% | |
| Q2 2022 | -9.3% | +2.1% | -15.1% | |
| Q1 2022 | +35.7% | +26.0% | -0.6% | |
| Q4 2019 | -2.6% | -1.3% | -16.4% | |
| Q4 2021 | -29.5% | -42.9% | -35.6% | |
| Q3 2020 | +1.3% | -13.1% | -15.4% | |
| Q3 2021 | -35.1% | -34.4% | -40.5% | |
| Q2 2020 | +5.1% | — | — | |
| Q1 2021 | +5.1% | — | — | |
| Q4 2020 | +5.1% | — | — | |
| Q2 2021 | -13.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro